Physician profile
Halana Rothbort
NPI 1255311403
$10,597.58
in general payments reported to CMS, 2019-2025
26 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $865 · 2021: $1,652 · 2022: $1,558 · 2023: $1,986 · 2024: $1,869 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,648.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,092.17 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $999.17 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $960.06 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $719.86 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $705.38 | 2019-2025 | Trintellix |
| Abbvie INC. | $696.40 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $680.12 | 2021-2025 | Caplyta |
| Neos Therapeutics, LP | $597.17 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $447.41 | 2020-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $429.78 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $427.76 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $427.01 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $368.77 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Tris Pharma INC | $331.11 | 2019-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $329.55 | 2025 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $251.11 | 2019-2024 | Invega Sustenna |
| Alfasigma USA, INC. | $236.77 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $225.69 | 2019-2020 | |
| Adlon Therapeutics L.P. | $184.24 | 2021 | |
| Vertical Pharmaceuticals, LLC | $118.90 | 2024-2025 | Relexxii |
| Shire North American Group INC | $89.59 | 2019 | |
| Almatica Pharma LLC | $88.54 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $71.47 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $70.79 | 2021-2022 | |
| Neuronetics, INC. | $27.62 | 2024 | Neurostar Tms Therapy System |
| Biogen, INC. | $21.14 | 2024 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halana Rothbort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.